Medical Condition News

RSS

Major East Coast academic medical center acquires BSD-500 Hyperthermia System

BSD Medical Corporation announced today that a major East Coast academic medical center has purchased a BSD-500 Hyperthermia System (BSD-500).

31 Jan 2013

Celsion's ThermoDox does not meet primary endpoint in Phase III HCC study

Celsion Corporation, a leading oncology drug development company, today announced that ThermoDox in combination with radiofrequency ablation (RFA) did not meet the primary endpoint of the Phase III HEAT Study in patients with hepatocellular carcinoma (HCC), also known as primary liver cancer.

31 Jan 2013

FDA approves Biotest's BIVIGAM to treat Primary Humoral Immunodeficiency

Biotest Pharmaceuticals Corporation (BPC), a wholly owned U.S. subsidiary of Biotest AG, recently announced the U.S. Food and Drug Administration's (FDA) approval of BIVIGAM, its new intravenous immune globulin, for the treatment of patients with Primary Humoral Immunodeficiency (PI).

31 Jan 2013

Top-line results from Vanda's tasimelteon Phase IIb/III study on major depressive disorder

Vanda Pharmaceuticals Inc. today announced top-line results of the Phase IIb/III clinical study (MAGELLAN) in Major Depressive Disorder (MDD), investigating the efficacy and safety of tasimelteon as a monotherapy in the treatment of patients with MDD.

31 Jan 2013

FDA allows Arteriocyte to commence Magellan System Phase I trial in thermal burn wounds

Arteriocyte, a leading biotechnology company with offices in Cleveland, Ohio and Hopkinton, Massachusetts announced today approval from the Food and Drug Administration (FDA) to initiate a Phase I clinical trial using its Magellan System technology in the treatment of thermal burn wounds.

31 Jan 2013

Velomedix commences rapid therapeutic hypothermia system pilot study in heart attack

Velomedix, a venture-backed medical device company advancing the field of therapeutic hypothermia, today announced the enrollment of the first patient in its VELOCITY pilot study.

31 Jan 2013

Resonance Health receives FDA marketing authorization for FerriScan R2-MRI device

The U.S. Food and Drug Administration recently announced the authorization of FerriScan R2-MRI to be marketed as an imaging companion diagnostic device for the safe and effective use of Exjade in patients with non-transfusion-dependent thalassemia.

31 Jan 2013

Study evaluates link between sedentary time and death among breast cancer survivors

Spending a lot of time watching television after breast cancer diagnosis is not linked to death in these breast cancer survivors. It appears that after accounting for self-reported physical activity levels after diagnosis, sedentary behavior was not an independent risk factor for death.

31 Jan 2013

Cerulean initiates CRLX101 Phase 2 study in extensive-stage small cell lung cancer

Cerulean Pharma Inc., a leader in developing dynamically tumor-targeted nanopharmaceuticals, today announced that the first patient has been dosed in a randomized Phase 2 study of its lead candidate, CRLX101, in patients with extensive-stage small cell lung cancer (SCLC) sensitive to first-line platinum-based chemotherapy.

31 Jan 2013

Northeast Ohio Medical University, CEL-SCI produce new investigational breast cancer vaccine

CEL-SCI Corporation announced that its longstanding collaboration with Northeast Ohio Medical University has produced a new investigational breast cancer vaccine which prevents and treats a HER-2/neu expressing breast cancer tumor in a mouse model of the disease.

31 Jan 2013

Adults should consume less than 5 g of salt and at least 3,510 mg of potassium per day: WHO

Adults should consume less than 2,000 mg of sodium, or 5 grams of salt, and at least 3,510 mg of potassium per day, according to new guidelines issued by the WHO. A person with either elevated sodium levels and low potassium levels could be at risk of raised blood pressure which increases the risk of heart disease and stroke.

31 Jan 2013

Interferon retreatment of chronic hepatitis C may be harmful

People with hepatitis C and chronic liver disease who relapsed or failed to respond to initial treatment are unlikely to improve on interferon retreatment. In fact, they may face an increased risk of dying sooner, and are likely to experience a variety of adverse effects, according to an updated systematic review published in The Cochrane Library.

31 Jan 2013

TB test offers rapid detection of TB and drug-resistant strains according to new study

A diagnostic test for tuberculosis (TB) can accurately and quickly detect both TB and drug-resistant strains, according to a new study. The authors of a new systematic review assessing the diagnostic accuracy of the Xpert® MTB/RIF test published in The Cochrane Library say their study can provide timely advice for clinicians and policymakers in countries where TB is a major public health problem.

31 Jan 2013

Selenium supplements do not reduce risk of developing heart disease according to current evidence

A systematic review published today in The Cochrane Library finds that in well-nourished adults current evidence does not support selenium for preventing heart disease.

31 Jan 2013

Cerebrolysin: a promising new treatment for dementia

Dementia patients may benefit from a promising new treatment called Cerebrolysin, according to the results of a systematic review published in The Cochrane Library. The authors brought together the most up-to-date evidence on Cerebrolysin as a treatment for vascular dementia.

31 Jan 2013

Congenital sight impairment cure grows closer

A cure for congenital sight impairment caused by lens damage is closer following research by scientists at Monash University.

31 Jan 2013

Teva terminates collaboration with CureTech

Teva Pharmaceutical Industries Ltd. announced today the termination of its collaboration with CureTech Ltd.

31 Jan 2013

Organizing the Nano World Cancer Day: A European multi-sites event in Paris, Braga and Berlin

In the framework of the World Cancer Day, the European Technology Platform of Nanomedicine (ETPN) and its partners will organize a European event on February the 1st on "How nanomedicine contributes to better cancer diagnostic and therapy". Similar and simultaneous events will be organized in France and Portugal, highlighting the importance of nanomedicine research for cancer on the European level.

31 Jan 2013

First payments awarded from 9/11 compensation fund

Fifteen first responders received payments from a federal fund set up to compensate people who were sickened by the Sept. 11 terrorist attacks. So far, fewer applications have been received by the fund than officials estimated they would receive.

31 Jan 2013

Being married and cohabiting reduces risk of heart attack in both men and women in all age groups

A large population-based study from Finland has shown that being unmarried increases the risk of fatal and non-fatal heart attack in both men and women whatever their age. Conversely, say the study investigators, especially among middle-aged couples, being married and cohabiting are associated with "considerably better prognosis of acute cardiac events both before hospitalization and after reaching the hospital alive".

31 Jan 2013

Medical Condition News

Major East Coast academic medical center acquires BSD-500 Hyperthermia System

Celsion's ThermoDox does not meet primary endpoint in Phase III HCC study

FDA approves Biotest's BIVIGAM to treat Primary Humoral Immunodeficiency

Top-line results from Vanda's tasimelteon Phase IIb/III study on major depressive disorder

FDA allows Arteriocyte to commence Magellan System Phase I trial in thermal burn wounds

Velomedix commences rapid therapeutic hypothermia system pilot study in heart attack

Resonance Health receives FDA marketing authorization for FerriScan R2-MRI device

Study evaluates link between sedentary time and death among breast cancer survivors

Cerulean initiates CRLX101 Phase 2 study in extensive-stage small cell lung cancer

Northeast Ohio Medical University, CEL-SCI produce new investigational breast cancer vaccine

Adults should consume less than 5 g of salt and at least 3,510 mg of potassium per day: WHO

Interferon retreatment of chronic hepatitis C may be harmful

TB test offers rapid detection of TB and drug-resistant strains according to new study

Selenium supplements do not reduce risk of developing heart disease according to current evidence

Cerebrolysin: a promising new treatment for dementia

Congenital sight impairment cure grows closer

Teva terminates collaboration with CureTech

Organizing the Nano World Cancer Day: A European multi-sites event in Paris, Braga and Berlin

First payments awarded from 9/11 compensation fund

Being married and cohabiting reduces risk of heart attack in both men and women in all age groups

Synthetic Psychedelics: A Growing Public Health Concern

How the Vutara VXL simplifies single-molecule imaging

How cohesin mechanics and nanotracker tech are redefining DNA research

Latest News